Special Issue

Nanomedicines for Immunotherapy

Message from the Guest Editor

Nanomedicine has emerged as a transformative platform for advancing cancer immunotherapy by enabling precise modulation of immune responses, targeted delivery of therapeutic agents, and reprogramming of the tumor microenvironment. Despite remarkable progress in immune checkpoint blockade, adoptive cell therapies, and cancer vaccines, therapeutic efficacy remains limited by systemic toxicities, poor tumor accumulation, immunosuppressive niches, and heterogeneous patient responses. Nanomedicines—ranging from polymeric nanoparticles, lipid-based carriers, inorganic materials, and biomimetic systems—offer unique opportunities to overcome these challenges by enhancing antigen presentation, reshaping innate immune pathways, modulating macrophage polarization, and integrating combinatorial strategies with radiotherapy or chemotherapy. This Special Issue aims to highlight recent advances in the design, characterization, and translational application of nanomaterials that enhance or synergize with immunotherapy. Contributions focusing on mechanistic insights, innovative drug delivery systems, and preclinical or clinical validation are particularly welcome.

Guest Editor

Dr. Mengyu Chang

Departments of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Deadline for manuscript submissions

30 June 2026

Pharmaceutics

About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

Author Benefits

High Visibility:
indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:
JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:
manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).